Key Points
- Julie Rubinstein sold a total of 311,046 shares of Adaptive Biotechnologies across multiple trades in early–mid March, raising roughly $4.36 million and reducing her stake to 494,920 shares (a 3.71% ownership decrease).
- Adaptive Biotechnologies posted a revenue beat—$71.7M, up 51% year-over-year—and EPS of ($0.09) that beat estimates, but the company remains unprofitable with negative margins; analysts hold a consensus Moderate Buy rating and an average target of $18.25.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $13.18, for a total value of $251,210.80. Following the completion of the transaction, the chief operating officer owned 494,920 shares of the company's stock, valued at approximately $6,523,045.60. The trade was a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Julie Rubinstein also recently made the following trade(s):
- On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total value of $255,594.60.
- On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07.
- On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
- On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
- On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total value of $285,672.80.
- On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
- On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total transaction of $495,056.00.
Adaptive Biotechnologies Stock Performance
Adaptive Biotechnologies stock opened at $13.28 on Thursday. Adaptive Biotechnologies Corporation has a one year low of $6.68 and a one year high of $20.76. The company has a 50-day simple moving average of $16.37 and a 200-day simple moving average of $15.88. The firm has a market capitalization of $2.04 billion, a P/E ratio of -33.20 and a beta of 2.19.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies's quarterly revenue was up 51.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) EPS. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Institutional Investors Weigh In On Adaptive Biotechnologies
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADPT. Rockefeller Capital Management L.P. lifted its position in Adaptive Biotechnologies by 50.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 7,577 shares of the company's stock worth $123,000 after purchasing an additional 2,550 shares during the period. Corient Private Wealth LLC increased its position in shares of Adaptive Biotechnologies by 3.4% during the 4th quarter. Corient Private Wealth LLC now owns 71,908 shares of the company's stock valued at $1,168,000 after purchasing an additional 2,347 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth $28,000. T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies in the 4th quarter worth $51,000. Finally, Invesco Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company's stock valued at $50,468,000 after buying an additional 2,216,595 shares during the period. Institutional investors own 99.17% of the company's stock.
Analyst Ratings Changes
ADPT has been the subject of several analyst reports. BTIG Research boosted their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Friday, February 6th. TD Cowen reissued a "buy" rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and an average target price of $18.25.
View Our Latest Research Report on Adaptive Biotechnologies
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
